We have searched far and wide for why Innovate Biopharmaceuticals (INNT) is flying high.

The news is absolutely scarce other than a recent a reverse recapitalization with Monster Digital (NASDAQ:MSDI). At the end of Q3 2017, the company had $174K in cash and operations consumed an average of ~$1M during the first three quarters of 2017 so it has an acute need for capital.

However, its leading drug candidate, Larazotide INN-202 has promise.

Larazotide Acetate or INN-202 is Innovate’s leading drug candidate for celiac disease (CeD) entering phase 3 clinical trials. INN-202 is a tight junction regulator, which helps restore “leaky” or open junctions to a normal state.

In CeD patients, ingestion of gluten causes disruption or opening of the tight junctions. The open junctions cause an inflammatory cascade within the intestinal epithelium that eventually destroys the intestinal villi, decreasing the surface area for absorption of nutrients, thus leading to a variety of diseases.

When ingested prior to a meal, larazotide may help keep the tight junctions closed, thus reducing the intestinal-inflammatory process in response to gluten.

Intestinal permeability is thought be involved in a variety of GI and autoimmune diseases and using a safe, non-absorbed drug like larazotide with more than 800 patient exposure, can allow for rapid proof-of-concept clinical trials.

Celiac disease remains an unmet need with no drugs approved. Patients diagnosed with celiac disease only have the gluten-free diet to manage their symptoms. There are more than 3 million celiac patients in the US and a similar number in Europe with another 15 million in the rest of the world.  Larazotide would be the first drug ever approved for celiac disease.

Larazotide is the only late-stage drug entering phase 3 trials with a path forward agreed upon with the FDA. After several clinical trials involving more than 800 patients and a phase 2b trial with 342 patients, larazotide has been shown to be safe and effective in a “real world setting” for celiac patients. Phase 3 trials are expected to begin in 2018.

Your input is required

Disagree, or have your own opinion? SUBMIT AN ARTICLE TODAY

Feel like commenting? Do you want to join a community of investors and start making money, for free? Then REGISTER now:

We want you to join our community

Benefits of signing up for a FREE membership now:

-No more costly delays in waiting for material

-Dozens of publications per week, including news coverage, earnings commentary, analysis, politics, and more

-Access to special guest contributions, including from WSJ, CNBC, and prolific independent authors

Ability to comment on articles

Access to our weekly newsletter

-Publish your own opinion/analysis

CLICK HERE: All you have to do is register, and join the community today. 

Thank you for your readership, and for your loyalty.

Regards,

Quad7Capital

——

Please Like And Share Our Content!